Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
NCT ID: NCT03797326
Last Updated: 2025-11-17
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
611 participants
INTERVENTIONAL
2019-02-12
2024-10-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)
NCT03776136
Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)
NCT02819518
Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)
NCT03898180
Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer
NCT02977468
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
NCT05091346
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pembrolizumab + Lenvatinib (Arm 1)
Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) plus lenvatinib 20 mg via oral capsule once a day (QD). Pembrolizumab will be administered for up to 35 cycles (up to 2 years). Lenvatinib will be administered until progressive disease or unacceptable toxicity (up to at least 2 years).
Pembrolizumab
Administered as an IV infusion on Day 1 Q3W.
Lenvatinib
Administered orally once a day during each 21-day cycle.
Lenvatinib Monotherapy (Arm 2)
Participants receive lenvatinib 24 mg via oral capsule QD, to be administered until progressive disease or unacceptable toxicity (up to at least 2 years).
Lenvatinib
Administered orally once a day during each 21-day cycle.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pembrolizumab
Administered as an IV infusion on Day 1 Q3W.
Lenvatinib
Administered orally once a day during each 21-day cycle.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must have progressed on or since the last treatment
* Has measurable disease per RECIST 1.1 (RANO for the GBM cohort) as assessed by the local site investigator/radiology and confirmed by BICR
* Has provided a PD-L1 evaluable archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated
* Male participants agree to use approved contraception during the treatment period for at least 7 days after the last dose of lenvatinib, or refrain from heterosexual intercourse during this period
* Female participants are not pregnant or breastfeeding, and are not a woman of childbearing potential (WOCBP), OR are a WOCBP that agrees to use contraception during the treatment period (or 14 days prior to the initiation of study treatment for oral contraception) and for at least 120 days post pembrolizumab, or 30 days post lenvatinib, whichever occurs last
* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 within 3 days of study treatment initiation
* Has adequate organ function
For Triple Negative Breast Cancer Participants:
* Has received one or 2 prior lines of therapy
* Has Lactate Dehydrogenase (LDH) \<2.0 x Upper Limit of Normal (ULN)
* Has locally determined results for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 tumor analyses
For Ovarian Cancer Participants:
\- Has primary ovarian cancer and has received 3 prior lines of therapy.
For Gastric Cancer Participants:
\- Has received 2 prior lines of therapy. Note: Gastric cancer will include participants with both gastric and gastroesophageal junction (GEJ) adenocarcinoma. Participants with squamous cell carcinoma histology are not eligible
For Colorectal Cancer Participants:
\- Has received 2 prior lines of therapy
For GBM Participants:
* Has failed initial systemic therapy for newly diagnosed GBM
* Have the following time periods elapsed before the projected start of scheduled study treatment: 1) at least 3 weeks from prior surgical resection, 2) at least 1 week from stereotactic biopsy, 3) at least 6 months from completion of prior radiotherapy, 4) at least 4 weeks (or 5 half-lives, whichever is shorter) from any investigational agent, 5) at least 4 weeks from cytotoxic therapy, 6) at least 6 weeks from antibodies, 7) at least 4 weeks (or 5 half-lives, whichever is shorter) from other antitumor therapies and 1 week for cancer vaccines
* Be neurologically stable (e.g. without a progression of neurologic symptoms or requiring escalating doses of systemic steroid therapy within last 2 weeks) and clinically stable
* Has histologically confirmed World Health Organization (WHO) Grade IV GBM
* Has locally determined result for O\^6-methylguanine-DNA methyltransferase (MGMT) analysis
For Biliary Tract Cancer Participants:
* Has received 1 prior line of therapy
* Child-Pugh Score, Class A: well-compensated disease. Child-Pugh Score of 5-6
For Pancreatic Cancer Participants:
* Has pathologically (histologically or cytologically) confirmed pancreatic ductal adenocarcinoma that is metastatic at enrollment
* Has received one or 2 prior lines of therapy
* Has received prior therapy with at least 1 (platinum-containing regimen or gemcitabine-containing regimen) but no more than 2 prior systemic therapies for unresectable or metastatic pancreatic cancer
Exclusion Criteria
* Has present or progressive accumulation of pleural, ascitic, or pericardial fluid requiring drainage or diuretic drugs within 2 weeks prior to enrollment (applies to all cohorts except the ovarian cancer cohort)
* Has radiographic evidence of encasement or invasion of a major blood vessel or of intratumoral cavitation. Participants with portal vein invasion (Vp4), inferior vena cava, or cardiac involvement based on imaging in the BTC cohort are not eligible for enrollment
* Has clinical significant hemoptysis or tumor bleeding within 2 weeks prior to the first dose of study treatment
* Has significant cardiovascular impairment within 12 months of the first dose of study treatment, such as history of congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, myocardial infarction or cerebrovascular accident (CVA), or cardiac arrhythmia associated with hemodynamic instability
* Has a history of arterial thromboembolism within 12 months of start of study treatment
* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.
* Has a serious nonhealing wound, ulcer or bone fracture
* Has had major surgery within 3 weeks prior to first dose of study interventions
* Has biologic response modifiers therapy (e.g. granulocyte colony-stimulating factor) within 4 weeks before study entry
* Has preexisting ≥Grade 3 gastrointestinal (GI) or non-gastrointestinal fistula
* Has received prior therapy with lenvatinib, an anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g. cytotoxic T-lymphocyte-associated protein 4 \[CTLA-4\], Tumor necrosis factor receptor superfamily, member 4 \[OX 40\], tumor necrosis factor receptor superfamily member 9 \[CD137\])
* Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to study treatment start
* If participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment
* Has received prior radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-central nervous system (CNS) disease
* Has received a live vaccine within 30 days prior to the first dose of study treatment
* Has known intolerance to lenvatinib (and/or any of the excipients)
* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment
* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study treatment
* Has known active CNS metastases and/or carcinomatous meningitis
* Has tumors involving the brain stem
* Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients
* Has an active autoimmune disease that has required systemic treatment in past 2 years
* Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis
* Has an active infection requiring systemic therapy
* Has a known history of human immunodeficiency virus (HIV) infection
* Has a known history of hepatitis B or known active hepatitis C virus infection
* Has a known history of active tuberculosis (TB; Bacillus tuberculosis)
* Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study treatment
* Has had an allogenic tissue/solid organ transplant (large organ transplants, stem-cell transplant requiring chronic immunosuppressant therapy necessary to prevent graft rejection)
For GBM Participants:
* Has carcinomatous meningitis
* Has recurrent tumor greater than 6 cm in maximum diameter
* Has tumor primarily localized to the brainstem or spinal cord
* Has presence of multifocal tumor, diffuse leptomeningeal or extracranial disease
* Has evidence of intratumoral or peritumoral hemorrhage on baseline magnetic resonance imaging (MRI) scan other than those that are grade ≤ 1 and either post-operative or stable on at least 2 consecutive MRI scans
* Has received Optune® TTFields within 2 weeks of study intervention
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eisai Inc.
INDUSTRY
Merck Sharp & Dohme LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Merck Sharp & Dohme LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
City of Hope ( Site 0002)
Duarte, California, United States
Cedars Sinai Medical Center ( Site 0003)
Los Angeles, California, United States
University of California Davis Comprehensive Cancer Center ( Site 0005)
Sacramento, California, United States
University of Colorado, Anschutz Cancer Pavilion ( Site 0007)
Aurora, Colorado, United States
University of Florida-Health Cancer Center-Orlando ( Site 0015)
Orlando, Florida, United States
Rutgers Cancer Institute of New Jersey ( Site 0009)
New Brunswick, New Jersey, United States
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0023)
New York, New York, United States
Sanford Fargo Medical Center ( Site 0059)
Fargo, North Dakota, United States
Lehigh Valley Hospital- Cedar Crest ( Site 0047)
Allentown, Pennsylvania, United States
Sanford Cancer Center ( Site 0058)
Sioux Falls, South Dakota, United States
West Cancer Center - East Campus ( Site 0018)
Germantown, Tennessee, United States
Mary Crowley Cancer Research Centers - Medical City Hospital ( Site 0049)
Dallas, Texas, United States
Swedish Medical Center ( Site 0021)
Seattle, Washington, United States
University of Wisconsin Carbone Cancer Center ( Site 0017)
Madison, Wisconsin, United States
Fundacion Favaloro para la Docencia e Investigacion Medica ( Site 2106)
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Hospital Aleman ( Site 2100)
Buenos Aires, Buenos Aires F.D., Argentina
Hospital Britanico de Buenos Aires ( Site 2109)
Ciudad de Buenos Aires, Buenos Aires F.D., Argentina
Instituto de Oncologia de Rosario ( Site 2105)
Rosario, Santa Fe Province, Argentina
CEMIC ( Site 2104)
Buenos Aires, , Argentina
IDIM Instituto de Diagnostico e Investigaciones Metabolicas ( Site 2101)
Caba, , Argentina
Royal Brisbane and Women s Hospital ( Site 0901)
Herston, Queensland, Australia
Alfred Health ( Site 0902)
Melbourne, Victoria, Australia
Sir Charles Gairdner Hospital ( Site 0903)
Nedlands, Western Australia, Australia
BC Cancer - Abbotsford ( Site 0200)
Abbotsford, British Columbia, Canada
CancerCare Manitoba ( Site 0201)
Winnipeg, Manitoba, Canada
Hamilton Health Sciences-Juravinski Cancer Centre ( Site 0208)
Hamilton, Ontario, Canada
Sunnybrook Research Institute ( Site 0207)
Toronto, Ontario, Canada
Princess Margaret Cancer Centre ( Site 0202)
Toronto, Ontario, Canada
Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0210)
Montreal, Quebec, Canada
CHU de Quebec Universite de Laval ( Site 0206)
Québec, Quebec, Canada
Fundacion Arturo Lopez Perez ( Site 1201)
Santiago, Region M. de Santiago, Chile
Pontificia Universidad Catolica de Chile ( Site 1202)
Santiago, Region M. de Santiago, Chile
Hospital Clinico Universidad de Chile ( Site 1200)
Santiago, Region M. de Santiago, Chile
Centro Investigación del Cáncer James Lind ( Site 1203)
Temuco, Región de la Araucanía, Chile
Fundacion Colombiana de Cancerologia Clinica Vida ( Site 1105)
Medellín, Antioquia, Colombia
Instituto Nacional de Cancerologia E.S.E ( Site 1102)
Bogotá, Bogota D.C., Colombia
Oncologos del Occidente S.A. ( Site 1106)
Pereira, Risaralda Department, Colombia
Fundacion Valle del Lili ( Site 1101)
Cali, Valle del Cauca Department, Colombia
Centre Antoine Lacassagne ( Site 0404)
Nice, Alpes-Maritimes, France
Centre Leon Berard ( Site 0405)
Lyon, Auvergne, France
Institut Claudius Regaud IUCT Oncopole ( Site 0403)
Toulouse, Haute-Garonne, France
Centre Oscar Lambret ( Site 0401)
Lille, Nord, France
Institut de Cancerologie de l Ouest Centre Rene Gauducheau ( Site 0402)
Saint-Herblain, Val-de-Marne, France
Institut Gustave Roussy ( Site 0400)
Villejuif, Val-de-Marne, France
Robert Bosch GmbH ( Site 0307)
Stuttgart, Baden-Wurttemberg, Germany
Universitaetsklinikum Regensburg ( Site 0304)
Regensburg, Bavaria, Germany
Universitaetsklinikum Frankfurt ( Site 0306)
Frankfurt am Main, Hesse, Germany
HELIOS Dr. Horst Schmidt Kliniken Wiesbaden ( Site 0301)
Wiesbaden, Hesse, Germany
SRH Wald-Klinikum Gera GmbH ( Site 0309)
Gera, Thuringia, Germany
Universitaetsklinikum Jena ( Site 0302)
Jena, Thuringia, Germany
Soroka Medical Center ( Site 0601)
Beersheba, , Israel
Rambam Medical Center ( Site 0602)
Haifa, , Israel
Hadassah Ein Kerem Medical Center ( Site 0604)
Jerusalem, , Israel
Chaim Sheba Medical Center ( Site 0600)
Ramat Gan, , Israel
Sourasky Medical Center ( Site 0603)
Tel Aviv, , Israel
Istituto Clinico Humanitas Research Hospital ( Site 1402)
Rozzano, Milano, Italy
Policlinico Le Scotte - A.O. Senese ( Site 1401)
Siena, Tuscany, Italy
Istituto Nazionale Tumori Fondazione Pascale ( Site 1400)
Napoli, , Italy
Fondazione Policlinico Universitario A. Gemelli ( Site 1403)
Roma, , Italy
Arkhangelsk Clinical Oncological Dispensary ( Site 1600)
Arkhangelsk, Arkhangelskaya oblast, Russia
Russian Oncological Research Center n.a. N.N. Blokhin ( Site 1604)
Moscow, Moscow, Russia
Leningrad Regional Oncology Center ( Site 1609)
Saint Petersburg, Sankt-Peterburg, Russia
Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 1610)
Saint Petersburg, Sankt-Peterburg, Russia
City Clinical Oncology Center ( Site 1608)
Saint Petersburg, Sankt-Peterburg, Russia
Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 1603)
Kazan', Tatarstan, Respublika, Russia
Asan Medical Center ( Site 1002)
Songpagu, Seoul, South Korea
Seoul National University Hospital ( Site 1000)
Seoul, , South Korea
Severance Hospital Yonsei University Health System ( Site 1001)
Seoul, , South Korea
Hospital Clinic i Provincial ( Site 0703)
Barcelona, , Spain
Hospital Universitario Gregorio Maranon ( Site 0701)
Madrid, , Spain
Clinica Universitaria de Navarra ( Site 0704)
Madrid, , Spain
Hospital Ramon y Cajal ( Site 0702)
Madrid, , Spain
Inselspital Universitaetsspital Bern ( Site 1705)
Bern, Canton of Bern, Switzerland
Kantonsspital St. Gallen ( Site 1702)
Sankt Gallen, Canton of St. Gallen, Switzerland
Ospedale Regionale di Bellinzona e Valli ( Site 1703)
Bellinzona, Canton Ticino, Switzerland
Kantonsspital Graubuenden ( Site 1704)
Chur, Kanton Graubünden, Switzerland
Hopitaux Universitaires de Geneve HUG ( Site 1701)
Geneva, , Switzerland
Universitaetsspital Zurich ( Site 1700)
Zurich, , Switzerland
National Cheng Kung University Hospital ( Site 3003)
Tainan, , Taiwan
National Taiwan University Hospital ( Site 3000)
Taipei, , Taiwan
Chulalongkorn University ( Site 5001)
Bangkok, Bangkok, Thailand
Ramathibodi Hospital. ( Site 5002)
Bangkok, Bangkok, Thailand
Siriraj Hospital ( Site 5003)
Bangkok, Bangkok, Thailand
Cambridge University Hospitals NHS Trust ( Site 0803)
Cambridge, Cambridgeshire, United Kingdom
Leicester Royal Infirmary. Univ. Hosp. of Leicester NHS Trust ( Site 0804)
Leicester, Leicestershire, United Kingdom
Guy's Hospital ( Site 0806)
London, London, City of, United Kingdom
Royal Marsden Hospital (Sutton) ( Site 0800)
London, Surrey, United Kingdom
Christie NHS Foundation Trust ( Site 0805)
Manchester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Gonzalez-Martin A, Chung HC, Saada-Bouzid E, Yanez E, Senellart H, Cassier PA, Basu B, Corr BR, Girda E, Dutcus C, Okpara CE, Ghori R, Jin F, Groisberg R, Lwin Z. Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study. Gynecol Oncol. 2024 Jul;186:182-190. doi: 10.1016/j.ygyno.2024.04.011. Epub 2024 May 7.
Chung HC, Saada-Bouzid E, Longo F, Yanez E, Im SA, Castanon E, Desautels DN, Graham DM, Garcia-Corbacho J, Lopez J, Dutcus C, Okpara CE, Ghori R, Jin F, Groisberg R, Korakis I. Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple-negative breast cancer: Results from the triple-negative breast cancer cohort of the phase 2 LEAP-005 Study. Cancer. 2024 Oct 1;130(19):3278-3288. doi: 10.1002/cncr.35387. Epub 2024 Jun 21.
Rha SY, Castanon E, Gill S, Senellart H, Lopez J, Marquez-Rodas I, Victoria I, Kim TM, Lwin Z, Burger MC, Simonelli M, Cassier PA, Hendifar AE, Ascierto PA, Dutcus C, Okpara CE, Ghori R, Jin F, Groisberg R, Villanueva L. Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP-005 study recurrent glioblastoma cohort. Cancer. 2025 Aug 15;131(16):e70015. doi: 10.1002/cncr.70015.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
Merck Clinical Trials Information
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MK-7902-005
Identifier Type: OTHER
Identifier Source: secondary_id
E7080-G000-224
Identifier Type: OTHER
Identifier Source: secondary_id
LEAP-005
Identifier Type: OTHER
Identifier Source: secondary_id
2018-003747-37
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
7902-005
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.